141 related articles for article (PubMed ID: 2010668)
1. The role of fibroblasts in organization and degradation of a fibrin clot.
Mirshahi M; Azzarone B; Soria J; Mirshahi F; Soria C
J Lab Clin Med; 1991 Apr; 117(4):274-81. PubMed ID: 2010668
[TBL] [Abstract][Full Text] [Related]
2. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
3. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
5. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
6. Clot lysis mediated by cultured human microvascular endothelial cells.
Speiser W; Anders E; Binder BR; Müller-Berghaus G
Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
8. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
9. Influence of homocysteine on fibrin network lysis.
Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255
[TBL] [Abstract][Full Text] [Related]
10. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation and lysis of blood clots induced by cells in vitro.
Knox P; Crooks S
J Cell Physiol; 1988 Jun; 135(3):467-73. PubMed ID: 2456288
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
14. Collagen and the development of resistance to fibrin clot lysis.
Mosesson MW
J Lab Clin Med; 1991 Apr; 117(4):265. PubMed ID: 2010667
[No Abstract] [Full Text] [Related]
15. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
16. The influence of poly-N-[(2,2-dimethyl-1,3-dioxolane)methyl]acrylamide on fibrin polymerization, cross-linking and clot structure.
Lai BF; Zou Y; Brooks DE; Kizhakkedathu JN
Biomaterials; 2010 Aug; 31(22):5749-58. PubMed ID: 20435346
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
19. [Importance of the structure of the clot in thrombolysis].
Soria C; Soria J; Mirshahi M; Desvignes P; Bonnet P; Caen JP
Ann Biol Clin (Paris); 1987; 45(2):207-11. PubMed ID: 2441630
[TBL] [Abstract][Full Text] [Related]
20. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
Wu JH; Siddiqui K; Diamond SL
Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
